Guidance, NICE advice and quality standards in development | Guidance

Showing 221 to 230 of 392

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]	Technology appraisal guidance	TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]	Technology appraisal guidance	TBC
Non-alcoholic fatty liver disease (NAFLD): assessment and management	NICE guideline	TBC
Non-invasive skin closure devices for surgical incisions (MT775)	Medical technologies guidance	TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]	Technology appraisal guidance	TBC